Building BioPhaS’s production expansion capacity
First written in FY2022. 4 of 16 entries say "Advanced", first in FY2023. Latest entry: 2026-08-06.
0 other companies' latest entry also says "Cited as achieved".
- FY2026Full-year revenue growth but an operating loss due to upfront costsAnnual report
「Sales of both pharmaceutical and medical packaging materials and single-use bags for the manufacture of biopharmaceuticals and other products (BioPhaS® (Biofas)) increased, resulting in higher sales for the business as a whole. In terms of earnings, despite the positive effect of higher sales, profit for the business as a whole declined due to higher depreciation expenses for the new building at the Company's Mie facility and continued upfront spending to expand sales of single-use bags for the manufacture of biopharmaceuticals and other products (BioPhaS® (Biofas)).」
BioPhaS generated higher full-year sales, but the Wellness business posted an operating loss of ¥201 million due to depreciation expenses for the new building at the Mie facility and upfront spending to expand sales. - FY2026-H1BioPhaS sales declined slightly; continued upfront spending to expand sales.Annual report
「Sales of single-use bags for the manufacture of biopharmaceuticals and other products (BioPhaS® (Biofas)) declined slightly. However, sales for the business as a whole increased, mainly because sales of pharmaceutical release films were strong in the pharmaceutical and medical packaging materials business. In terms of earnings, despite the positive effect of higher sales, profit for the business as a whole declined due to higher depreciation expenses for the new building at the Company's Mie facility and continued upfront spending to expand sales of single-use bags for the manufacture of biopharmaceuticals and other products (BioPhaS® (Biofas)).」
BioPhaS sales declined slightly, while upfront spending to expand sales and depreciation expenses for the new building at the Mie facility reduced profit in the Wellness business. - FY2025RestatedAnnual report
「Strengthen the production and supply system for single-use bags used in the manufacture of biopharmaceuticals and other products. Expand services and strengthen collaboration with external partners.」
Reconfirmed the policy of strengthening the production and supply system, services, and collaboration with external partners for single-use bags, including BioPhaS. - FY2024AdvancedAnnual report
「Single-use bags and related products for biopharmaceutical manufacturing, including BioPhaS® (バイファス), became a growth-driving business over the past 3 years, and production capacity at the Mie Plant will be expanded as the customer base grows.」
Positioned BioPhaS as a growth-driving business over the past 3 years and specified plans to expand production capacity at the Mie facility to meet increased customer demand. - FY2024-Q3RestatedAnnual report
「Sales of single-use bags and related products for biopharmaceutical manufacturing fell below the year-earlier level as demand for vaccines declined.」
Reconfirmed that year-on-year revenue from single-use bags and other products, including BioPhaS, continued to decline due to lower demand for vaccines. - FY2024-Q2Revenue decline due to lower vaccine-related demand continuedAnnual report
「Sales of single-use bags and related products for biopharmaceutical manufacturing fell below the year-earlier level as demand for vaccines declined.」
Sales of single-use bags and other products, including BioPhaS, fell below the year-earlier level due to lower demand for vaccines. - FY2024-Q1Revenue from single-use bags and other products declined againAnnual report
「Although revenue from single-use bags and related products for biopharmaceutical manufacturing declined, overall revenue increased as sales of pharmaceutical and medical packaging grew, primarily at overseas subsidiaries.」
Single-use bags and related products, including BioPhaS, which generated higher revenue in the previous full fiscal year, posted lower revenue in the current quarter. Meanwhile, growth in pharmaceutical and medical packaging sales, primarily at overseas subsidiaries, drove higher revenue for the Wellness business overall. - FY2023AdvancedAnnual report
「Overseas subsidiaries posted substantial sales growth in pharmaceutical and medical packaging materials, while revenue also increased for single-use bags and related products used in the manufacture of biopharmaceuticals and other products.」
Single-use bags and other products, including BioPhaS, generated full-year revenue growth together with pharmaceutical and medical packaging sold by overseas subsidiaries, indicating progress in the businesses targeted for expanded production capacity. - FY2023-Q3RestatedAnnual report
「Overseas subsidiaries posted substantial sales growth in pharmaceutical and medical packaging materials, while revenue also increased for single-use bags and related products used in the manufacture of biopharmaceuticals and other products.」
Reconfirmed higher revenue from the single-use bags and other products targeted for expanded production, together with pharmaceutical and medical packaging sold by overseas subsidiaries. - FY2023-Q2Revenue from single-use bags and other products turned from a decline to growthAnnual report
「Overseas subsidiaries posted substantial sales growth in pharmaceutical and medical packaging materials, while revenue also increased for single-use bags and related products used in the manufacture of biopharmaceuticals and other products.」
Single-use bags and related products, which had posted lower revenue in the previous quarter, generated higher revenue in the first 2 quarters cumulatively. Revenue for the Wellness business overall increased 18.1% year on year. - FY2023-Q1Revenue from single-use bags and other products declinedAnnual report
「Although revenue from single-use bags and related products for biopharmaceutical manufacturing declined, revenue for the business overall increased, owing in part to significant growth in sales of pharmaceutical and medical packaging by overseas subsidiaries.」
While revenue from the single-use bags and related products targeted for expanded production declined, overall Wellness business revenue increased due to growth in pharmaceutical and medical packaging sales by overseas subsidiaries. - FY2022First statedAnnual report
「Building production capacity for BioPhaS® (バイファス), single-use bags and related products for biopharmaceutical manufacturing」
For the strong-performing single-use bags and other products for biopharmaceutical manufacturing, building production capacity was identified for the first time as a business strategy priority.